GlassScriptPhysician profile
Andrew J Moses
NPI 1669765533
$2,212.92
in general payments reported to CMS, 2019-2025
27 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $339 · 2021: $82.21 · 2022: $286 · 2023: $432 · 2024: $232 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $300.63 | 2019-2025 | |
| Pfizer INC. | $270.73 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $227.24 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $192.76 | 2019-2023 | Xarelto |
| Amgen INC. | $182.93 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $144.79 | 2020-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $105.28 | 2019-2025 | Eliquis, Camzyos |
| Braemar Manufacturing, LLC | $95.63 | 2019 | |
| Philips North America LLC | $83.07 | 2020-2024 | (Ck4) Mcot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.32 | 2023-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $63.64 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $61.20 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $54.81 | 2022-2023 | Definity |
| Baxter Healthcare | $49.92 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $46.48 | 2024 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $35.62 | 2019 | |
| Merck Sharp & Dohme LLC | $35.16 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $33.80 | 2023 | Optimizer |
| Cardiva Medical, INC. | $30.88 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.36 | 2019 | |
| Amarin Pharma, INC. | $19.07 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.02 | 2025 | |
| W. L. Gore & Associates, INC. | $15.44 | 2023 | Gore Cardioform Septal Occluder |
| Allergan, INC. | $15.21 | 2019 | |
| Scpharmaceuticals INC. | $13.83 | 2023 | |
| Novo Nordisk INC | $12.00 | 2020 | |
| Ge Healthcare | $8.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.